Amphastar Pharmaceuticals Inc v. Aventis Pharma SA

1 2

3

4

5

6 7 8 UNITED STATES DISTRICT COURT 9 CENTRAL DISTRICT OF CALIFORNIA 10

AMPHASTAR PHARMACEUTICALS

11 Case No. 5:09-cv-00023-SHK

INC.,

12 Plaintiff,

13 OPINION AND ORDER v. 14 AVENTIS PHARMA S.A., et al., 15 Defendants. 16 17 18 Defendants Aventis Pharma S.A., Aventis Pharmaceuticals, Inc., and Sanofi- 19 Aventis S.A. (collectively “Defendants”) filed their Supplemental Submission 20 Pursuant to the Court’s November 13, 2020 Fee Amount Order (“Submission” or 21 “Sub.”) against Plaintiff Amphastar Pharmaceuticals, Inc. (“Plaintiff”). Electronic 22 Case Filing Number (“ECF No.”) 634, Sub. Pursuant to 28 U.S.C. § 636(c), the 23 parties have consented to the jurisdiction of the undersigned United States 24 Magistrate Judge. See ECF No. 607, Statement of Consent to Proceed before a 25 United States Magistrate Judge (“Consent Statement”). For the reasons discussed 26 below, the Court GRANTS Defendants’ Submission in part. 27 / / / 1 I. BACKGROUND 2 The procedural history of this case, which the…